Literature DB >> 12573814

Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency.

J Imperato-McGinley1, Y-S Zhu.   

Abstract

Dihydrotestosterone (DHT), a potent androgen, is converted from testosterone by 5alpha-reductase isozymes. There are two 5alpha-reductase isozymes, type 1 and type 2 in humans and animals. These two isozymes have differential biochemical and molecular features. Mutations in type 2 isozyme cause male pseudohermaphroditism, and many mutations have been reported from various ethnic groups. The affected 46XY individuals have high normal to elevated plasma testosterone levels with decreased DHT levels and elevated testosterone/DHT ratios. They have ambiguous external genitalia at birth so that they are believed to be girls and are often raised as such. However, Wolffian differentiation occurs normally and they have epididymides, vas deferens and seminal vesicles. Virilization occurs at puberty frequently with a gender role change. The prostate in adulthood is small and rudimentary, and facial and body hair is absent or decreased. Balding has not been reported. Spermatogenesis is normal if the testes are descended. The clinical, biochemical and molecular genetic analyses of 5alpha-reductase-2 deficiency highlight the significance of DHT in male sexual differentiation and male pathophysiology. Copyright 2002 Published by Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12573814     DOI: 10.1016/s0303-7207(02)00368-4

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  48 in total

Review 1.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

2.  A novel mutation of 5alpha-steroid reductase 2 deficiency (CD 65 ALA-PRO) with severe virilization defect in a Turkish family and difficulty in gender assignment.

Authors:  Senay Savas Erdeve; Zehra Aycan; Merih Berberoglu; Zeynep Siklar; Bulent Hacihamdioglu; Kadir Sipahi; Nejat Akar; Gonul Ocal
Journal:  Eur J Pediatr       Date:  2010-02-24       Impact factor: 3.183

3.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

Review 4.  A genetic approach to dissect sexually dimorphic behaviors.

Authors:  Scott A Juntti; Jennifer K Coats; Nirao M Shah
Journal:  Horm Behav       Date:  2008-01-05       Impact factor: 3.587

Review 5.  Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.

Authors:  Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

Review 6.  Practical approach to steroid 5alpha-reductase type 2 deficiency.

Authors:  Chong Kun Cheon
Journal:  Eur J Pediatr       Date:  2010-03-28       Impact factor: 3.183

7.  Steroid 5α-reductase 2 deficiency leads to reduced dominance-related and impulse-control behaviors.

Authors:  Laura J Mosher; Sean C Godar; Marc Morissette; Kenneth M McFarlin; Simona Scheggi; Carla Gambarana; Stephen C Fowler; Thérèse Di Paolo; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2018-02-16       Impact factor: 4.905

Review 8.  Androgen replacement therapy: present and future.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.

Authors:  Donald J Tindall; Roger S Rittmaster
Journal:  J Urol       Date:  2008-02-20       Impact factor: 7.450

Review 10.  The adrenal cortex and sexual differentiation during early human development.

Authors:  Daniel J Asby; Wiebke Arlt; Neil A Hanley
Journal:  Rev Endocr Metab Disord       Date:  2009-03       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.